Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,852
datasets available to search
ShareScore release 0.7.1
Dataset results
2,852 results for “Hepatocellular carcinoma”
Multi-omics analysis reveals the link between Treg distribution and therapy efficacy in Hepatocellular Carcinoma patients treated with tremelimumab plus durvalumab
<p><strong><span><span>Introduction</span></span></strong></p> <p><span>Hepatocellular carcinoma (HCC) remains a significant contributor to cancer-related deaths. Immunotherapy, either alone or in combination, has emerged as the standard treatment for advanced HCC. Notably, the combination of durvalumab (dur) and tremelimumab (trem) has received FDA approval based on findings from the HIMALAYA trial. However, comprehensive studies elucidating immune responses are lacking. We conducted a thorough analysis utilizing clinical samples from tumor biopsies to understand the mechanism of response.</span></p> <p><strong><span><span>Methods</span></span></strong></p> <p><span>Multiplexed immunofluorescence microscopy was used to analyze immune cell infiltration in primary human liver cancer samples. We developed and validated a comprehensive 37-plex antibody panel for immunofluorescence imaging of human FFPE samples. We applied highly multiplexed co-detection by indexing (CODEX) technology to simultaneously profile in situ expression of 37 proteins at sub-cellular resolution in 20 HCC patient samples using whole slide scanning. We established an image analysis pipeline to quantify all major cell populations in the human liver using supervised manual gating and unsupervised clustering algorithms using the exported matrix of the marker expression and spatial information. Clinical metadata including sex, gender, ethnicity, pretreatment, and histopathological reports are available for all patient samples.</span></p> <p><strong><span><span>Results</span></span></strong></p> <p><span><span>Using high-dimensional spatially resolved quantitative analysis of multiplexed immunofluorescence microscopy images, we generated a unique dataset and profiled the single-cell pathology landscape for human HCC treated with immunotherapy. In situ phenotyping of 400,000 single cells (including 130,000 CD45+ immune cells) allowed for the quantification of cell phenotype clusters, differential analysis of activation markers, and spatial features of each individual cell. This analysis revealed the comprehensive profile of the cell composition and spatial interactions of different cells in the TiME of patients treated with immunotherapy. Further details on the study can be obtained in our paper once it’s published.</span></span></p> <p><strong><span><span>Conclusion</span></span></strong></p> <p><span><span>We developed the CODEX panel for FFPE biopsy samples of HCC patients.</span></span></p>
RNA sequencing dataset for prediction of liver hepatocellular carcinoma using SIMON analysis
<p>The LIHC dataset was used for data mining and for the generation of machine learning model for the detection of liver hepatocellular carcinoma cells (LIHC) using the SIMON platform as described in the "SIMON: open-source knowledge discovery platform" publication (<a href="https://doi.org/10.1101/2020.08.16.252767">https://doi.org/10.1101/2020.08.16.252767</a>). The LIHC dataset was obtained from the <em>GSEABenchmarkeR</em> package ( <a href="https://doi.org/10.1093/bib/bbz158">https://doi.org/10.1093/bib/bbz158</a>) and it contains RNA expression data from 374 liver hepatocellular carcinoma (LIHC) cells and 50 adjacent normal cells.</p>
WAW-TACE: A Hepatocellular Carcinoma Multiphase CT Dataset with Segmentations, Radiomics Features, and Clinical Data
<p>The WAW-TACE dataset contains multiphase abdominal CT images from N=233 treatment-naive patients with HCC treated with TACE in monotherapy, annotated with N=377 hand-crafted liver tumor masks, automated segmentations of multiple internal organs, extracted radiomics features, and corresponding extensive clinical data.</p> <p> </p>
Dataset for Repeated double cross validation applied to the PCA-LDA classification of SERS spectra: a case study with serum samples from hepatocellular carcinoma patients
<p>This dataset contains all the spectra used in the paper "Repeated double cross validation applied to the PCA-LDA classification of SERS spectra: a case study with serum samples from hepatocellular carcinoma patients", plus the R code to import the TXT (ASCII) files into a dataset, preprocess data, set-up and cross validate the PCA-LDA model and generate the figures shown in the paper.</p> <p>Data are available in 2 different formats: </p> <p>- 1 compressed archive ("dataset.zip") containing all the 144 TXT files (1 file = 1 spectrum) </p> <p>- 1 single CSV file (“dataset.csv”) with all the 144 spectra in the form of a table. The data are structured as follow, with each row being 1 spectrum, preceded by metadata: "acquisition_date", "substrate_batch", "class", "sample_code".</p> <p>The code for R is available as a single file "Rcode.R".</p> <p> </p>
Supplementary Tables - Re-analysis of hepatitis B virus integration sites reveals potential new loci associated with oncogenesis in hepatocellular carcinoma
<p>------------------------------------------------------------</p> <p><strong>Supplementary Tables</strong></p> <p>supplementary_table.xlsx</p> <ul> <li>T2T-CHM13_human</li> <li>T2T-CHM13_hbv</li> <li>GRCh38_human</li> <li>GRCh38_hbv</li> <li>GRCh_human_annotation</li> <li>meta</li> </ul> <p>------------------------------------------------------------</p> <p><strong>Re-analysis of hepatitis B virus integration sites reveals potential new loci associated with oncogenesis in hepatocellular carcinoma</strong><br> <a href="https://doi.org/10.5501/wjv.v12.i3.209">https://doi.org/10.5501/wjv.v12.i3.209</a></p><br> <p><strong>BACKGROUND</strong></p> <p>Hepatitis B virus (HBV) is a major cause of hepatocellular carcinoma (HCC). HBV DNA can get integrated into the hepatocyte genome to promote carcinogenesis. However, the precise mechanism by which the integrated HBV genome promotes HCC has not been elucidated.</p> <p><strong>AIM</strong></p> <p>To analyze the features of HBV integration in HCC using a new reference database and integration detection method.</p> <p><strong>METHODS</strong></p> <p>Published data, consisting of 426 Liver tumor samples and 426 paired adjacent non-tumor samples, were re-analyzed to identify the integration sites. Genome Reference Consortium Human Build 38 (GRCh38) and Telomere-to-Telomere Consortium CHM13 (T2T-CHM13 (v2.0)) were used as the human reference genomes. In contrast, human genome 19 (hg19) was used in the original study. In addition, GRIDSS VIRUSBreakend was used to detect HBV integration sites, whereas high-throughput viral integration detection (HIVID) was applied in the original study (HIVID-hg19).</p> <p><strong>RESULTS</strong></p> <p>A total of 5361 integration sites were detected using T2T-CHM13. In the tumor samples, integration hotspots in the cancer driver genes, such as TERT and KMT2B, were consistent with those in the original study. GRIDSS VIRUSBreakend detected integrations in more samples than by HIVID-hg19. Enrichment of integration was observed at chromosome 11q13.3, including the CCND1 pro-moter, in tumor samples. Recurrent integration sites were observed in mitochondrial genes.</p> <p><strong>CONCLUSION</strong></p> <p>GRIDSS VIRUSBreakend using T2T-CHM13 is accurate and sensitive in detecting HBV integration. Re-analysis provides new insights into the regions of HBV integration and their potential roles in HCC development.</p>
Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma.
ClinicalTrials.gov study NCT01737827. IPD Sharing: YES. Countries: 4. Publications: 1.
A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma
ClinicalTrials.gov study NCT03586973. IPD Sharing: YES. Countries: 1. Publications: 1.
Spatial mapping of the hepatocellular carcinoma landscape identifies unique intratumoural perivascular-immune neighbourhoods
<p>The uploaded data includes results from imaging mass cytometry (IMC) data collected from hepatocellular carcinoma patients. The associated publication can be found <a href="https://journals.lww.com/hepcomm/fulltext/2024/11010/spatial_mapping_of_the_hcc_landscape_identifies.11.aspx">here</a> (Marsh-Wakefield <em>et al.</em>, 2024, <em>Hepatology Communications</em>).</p> <p>The CSV file contains segmented cells from IMC data. This includes the Patient, ROI, and Group each cell is assigned. Marker signal intensities underwent arcsine transformation and were rescaled. The “simprof_cluster” column contains the final iteration of clustering following initial X-shift clustering.</p> <p>Notes on additional columns:</p> <ul> <li>“Sample” is barcoded such that the first three digits are the ablation number, followed by the region on the TMA, the group, and the patient. I.e., “[ablation.number]_[TMA.location]_[group]_[patient]”.</li> <li>“x” and “y” refer to the coordinates of samples.</li> <li>“Group” refers to the tissue type. Included non-tumour (NT), invasive margin (IM), and tumour (T) regions.</li> <li>The area for each ROI has been calculated (µm^2 and mm^2).</li> <li>“Batch” refers to TMA.</li> <li>In most cases each area from each patient has three ablation sites. Three samples have an extra ablation site due to technical difficulties during the ablation, and hence have a “split” sample.</li> </ul> <p>The PDF file contains patient information associated with the IMC data.</p> <p>DOI of dataset:</p> <p>10.5281/zenodo.10622397</p> <p>Any further questions can be addressed to Felix Marsh-Wakefield felix.marsh-wakefield@sydney.edu.au</p>
Characterization of the tumor-immune microenvironment in hepatocellular carcinoma by highly multiplexed imaging mass cytometry
<p>Imaging mass cytometry data of 54 HCC patients. </p> <ul> <li>DC_img_normalized: Preprocessed and normalized multistack .tiff images. Each stack represents one channel. Channel annotations are stored in the ICICohort_panel.csv file. ROIs are located in the tumor, interface and adjacent liver as indicated in the file name.</li> <li>DC_cellmasks: Masks identifying individual cells on the images.</li> <li>DC_stromamasks: Masks identifying stromal and parenchymal regions on the image.</li> <li>DCCohort_panel.csv: table containing channel information (metal tag and marker).</li> </ul> <p>Patient metadata may be found as supplementary table 2 of DOI <a href="https://doi.org/10.1136/gutjnl-2024-332837" target="_blank" rel="noopener noreferrer"> 10.1136/gutjnl-2024-332837 </a>.</p>
NOVEL MOLECULAR TARGETS FOR HEPATOCELLULAR CARCINOMA
<p><strong>Abstract: </strong>Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer globally. Indeed, only few treatments are available, most of which are effective only for the early stages of the disease. Therefore, there is an urgent needing of potential markers for a specifically targeted therapy. Candidate proteins were selected from datasets of The Human Protein Atlas, in order to identify specific tumor-associated proteins overexpressed in HCC samples associated with poor prognosis. Potential epitopes were predicted from such proteins and homology with peptides derived from viral proteins was assessed. A multiparametric validation was performed, including recognition by PBMCs from HCC-patients and healthy donors, showing a T cell cross-reactivity with paired epitopes. These results provide novel HCC-specific Tumor-associated antigens (TAAs)TAAs for immunotherapeutic anti-HCC strategies potentially able to expand pre-existing virus-specific CD8<sup>+</sup> T cells with superior anti-cancer efficacy.</p>
Expression of CDCA2 in hepatocellular carcinoma by immunohistochemistry and patients' information
<p>Cohort of hepatocellular carcinoma patients enrolled in the study entitled "Cell division cycle associated 2 (CDCA2) upregulation promotes the progression of hepatocellular carcinoma in a p53-dependant mannar". CDCA2 expression in paraffin-embedded liver cancer tissue sections was evaluated by immunohistochemistry. Patients' clinicopathological information was collected.</p>
Raw Data for the article: HCV Interplay With Mir34a: Implications in Hepatocellular Carcinoma
<p>Since its identification, HCV has been considered one of the main causes of hepatitis and liver cancer. Currently, the molecular mechanisms of HCC development induced by HCV infection have not been sufficiently clarified. The recent discovery of novel treatments that inhibit HCV replication gave rise to new questions concerning HCC mechanisms. In particular, the HCV eradication mediated by new direct-acting antiviral (DAAs) drugs does not exclude the possibility of <em>de novo</em> HCC development; this finding opened more questions on the interplay between liver cells and the virus. Different groups have investigated the pathways leading to cancer recurrence in patients treated with DAAs. For this reason, we tried to gain molecular insights into the changes induced by HCV infection in the target liver cells. In particular, we observed an increase in microRNA34a (miR34a) expression following HCV infection of HCC cell line Huh7.5. In addition, Huh7.5 treated with extracellular vesicles (EVs) from the previously HCV-infected Huh7.5 underwent apoptosis. Since miR34 expression was increased in Huh7.5 EVs, we hypothesized a paracrine mechanism of viral infection mediated by miR34a cargo of EVs. The balance between viral infection and cell transformation may raise some questions on the possible use of antiviral drugs in association with antineoplastic treatment.</p>
Raw Data for the article: Clinical and Molecular-Based Approach in the Evaluation of Hepatocellular Carcinoma Recurrence after Radical Liver Resection
<p><strong>Background: </strong>Hepatic resection remains the treatment of choice for patients with early-stage HCC with preserved liver function. Unfortunately, however, the majority of patients develop tumor recurrence. While several clinical factors were found to be associated with tumor recurrence, HCC pathogenesis is a complex process of accumulation of somatic genomic alterations, which leads to a huge molecular heterogeneity that has not been completely understood. The aim of this study is to complement potentially predictive clinical and pathological factors with next-generation sequencing genomic profiling and loss of heterozygosity analysis.</p> <p><strong>Methods: </strong>124 HCC patients, who underwent a primary hepatic resection from January 2016 to December 2019, were recruited for this study. Next-generation sequencing (NGS) analysis and allelic imbalance assessment in a case-control subgroup analysis were performed. A time-to-recurrence analysis was performed as well by means of Kaplan-Meier estimators.</p> <p><strong>Results: </strong>Cumulative number of HCC recurrences were 26 (21%) and 32 (26%), respectively, one and two years after surgery. Kaplan-Meier estimates for the probability of recurrence amounted to 37% (95% C.I.: 24-47) and to 51% (95% C.I.: 35-62), after one and two years, respectively. Multivariable analysis identified as independent predictors of HCC recurrence: hepatitis C virus (HCV) infection (HR: 1.96, 95%C.I.: 0.91-4.24, <em>p</em> = 0.085), serum bilirubin levels (HR: 5.32, 95%C.I.: 2.07-13.69, <em>p</em> = 0.001), number of nodules (HR: 1.63, 95%C.I.: 1.12-2.38, <em>p</em> = 0.011) and size of the larger nodule (HR: 1.11, 95%C.I.: 1.03-1.18, <em>p</em> = 0.004). Time-to-recurrence analysis showed that loss of heterozygosity in the <em>PTEN</em> loci (involved in the PI3K/AKT/mTOR signaling pathway) was significantly associated with a lower risk of HCC recurrence (HR: 0.35, 95%C.I.: 0.13-0.93, <em>p</em> = 0.036).</p> <p><strong>Conclusions: </strong>multiple alterations of cancer genes are associated with HCC progression. In particular, the evidence of a specific AI mutation presented in 20 patients seemed to have a protective effect on the risk of HCC recurrence.</p>
Source data for publication "A multimodal atlas of hepatocellular carcinoma reveals convergent evolutionary paths and 'bad apple' effect on clinical trajectory" in Journal of Hepatology
<p>Processed genomic and transcriptomic data for the publication <a href="https://doi.org/10.1016/j.jhep.2024.05.017">https://doi.org/10.1016/j.jhep.2024.05.017</a>.</p> <p>cnv_segmentation.tsv: CNV segmentation file from Sequenza.</p> <p>cnv_arm.tsv: Significant arm level CNV events called by GISTIC, from broad_values_by_arm.txt file.</p> <p>cnv_gene.tsv: Gene level CNV events called by GISTIC, from all_threshold_by_genes.txt file. </p> <p>RNA_raw_counts.tsv: Raw RNA-seq read counts from featureCounts.</p> <p>snv_indel.tsv: All SNV and Indel called with annotation from Funcotator.</p> <p> </p>
Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma
<p>This repository contains imaging mass cytometry (IMC) data and associated files for the publication "Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma". Code used to analyze these data can be found at https://github.com/FertigLab/HCCTLS. Raw IMC data have been uploaded as .mcd files (n=10). The file "IMCpanel.xlsx" indicates the antibodies used for each IMC channel. In addition, we have uploaded .tiff files (n=38) generated from each .mcd, which were used to identify and annotate individual tertiary lymphoid structures (TLS) as some ROI had multiple TLS. The file "Updated Catalogue of TLS with S numbers.xlsx" indicates which TLS correspond to each ROI in the .mcd files. To determine the area of each TLS, .tiff files were annotated using ImageJ and the area of each TLS was exported and stored in the file, "TLS_selection_area_pixels.csv". The XY coordinates of individual TLS were obtained by using FlowJo software to annotate .fcs files resulting from single cell segmentation of each ROI. </p>
Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches
<p>Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer globally. Indeed, there is a single drug approved as first-line systemic therapy in advanced unresectable HCC, providing a very limited survival benefit. In earlier stages, 5-year survival rates after surgical and loco-regional therapies are extremely variable depending on the stage of disease.</p> <p>Nevertheless, HCC is considered an immunogenic tumor arising in chronically inflamed livers. </p> <p>In such a scenario, immunotherapy strategies for HCC, in particular combinations including cancer vaccines, may represent a key therapeutic tool to improve clinical outcome in HCC patients. However, a lot of improvement is needed given the disappointing results obtained so far.</p>
Long-Term Survival and Curative-Intent Treatment in Hepatitis B or C Virus-Associated Hepatocellular Carcinoma Patients Diagnosed during Screening
<p>We uploaded the image of the mansucript <strong>Long-Term Survival and Curative-Intent Treatment in Hepatitis B or C Virus-Associated Hepatocellular Carcinoma Patients Diagnosed during Screening </strong>accepted on Biology.</p>
Raw Data for the article: How important is the role of iterative liver direct surgery in patients with hepatocellular carcinoma for a transplant center located in an area with a low rate of deceased donation?
<p><strong>Introduction: </strong>Hepatocellular carcinoma (HCC) accounts for nearly 90% of primary liver cancers, with estimates of over 1 million people affected by 2025. We aimed to explore the impacting role of an iterative surgical treatment approach in a cohort of HCC patients within the Milan criteria, associated with clinical risk factors for tumor recurrence (RHCC) after liver transplant (LT) and loco-regional therapies (LRT), as well as liver resection (LR) and/or microwave thermal ablation (MWTA).</p> <p><strong>Methods: </strong>We retrospectively analyzed our experience performed during an 8-year period between January 2013 and December 2021 in patients treated for HCC, focusing on describing the impact on preoperative end-stage liver disease severity, oncologic staging, tumor characteristics, and surgical treatments. The Cox model was used to evaluate variables that could predict relapse risks. Relapse risk curves were calculated according to the Kaplan-Meier method, and the log-rank test was used to compare them.</p> <p><strong>Results: </strong>There were 557 HCC patients treated with a first-line approach of LR and/or LRTs (<em>n</em> = 335) or LT (<em>n</em> = 222). The median age at initial transplantation was 59 versus 68 for those whose first surgical approach was LR and/or LRT. In univariate analysis with the Cox model, nodule size was the single predictor of recurrence of HCC in the posttreatment setting (HR: 1.61, 95% CI: 1.05-2.47, <em>p</em> = 0.030). For the LRT group, we have enlightened the following clinical characteristics as significantly associated with RHCC: hepatitis B virus infection (which has a protective role with HR: 0.34, 95% CI: 0.13-0.94, <em>p</em> = 0.038), number of HCC nodules (HR: 1.54, 95% CI: 1.22-1.94, <em>p</em> < 0.001), size of the largest nodule (HR: 1.06, 95% CI: 1.01-1.12, <em>p</em> = 0.023), serum bilirubin (HR: 1.57, 95% CI: 1.03-2.40, <em>p</em> = 0.038), and international normalized ratio (HR: 16.40, 95% CI: 2.30-118.0, <em>p</em> = 0.006). Among the overall 111 patients with RHCC in the LRT group, 33 were iteratively treated with further curative treatment (12 were treated with LR, two with MWTA, three with a combined LR-MWTA treatment, and 16 underwent LT). Only one of 18 recurrent patients previously treated with LT underwent LR. For these RHCC patients, multivariable analysis showed the protective roles of LT for primary RHCC after IDLS (HR: 0.06, 95% CI: 0.01-0.36, <em>p</em> = 0.002), of the time relapsed between the first and second IDLS treatments (HR: 0.97, 95% CI: 0.94-0.99, <em>p</em> = 0.044), and the impact of previous minimally invasive treatment (HR: 0.28, 95% CI: 0.08-1.00, <em>p</em> = 0.051).</p> <p><strong>Conclusion: </strong>The coexistence of RHCC with underlying cirrhosis increases the complexity of assessing the net health benefit of ILDS before LT. Minimally invasive surgical therapies and time to HCC relapse should be considered an outcome in randomized clinical trials because they have a relevant impact on tumor-free survival.</p>
Hepatocellular carcinoma (HCC) Tumor microenvironment is more suppressive than colorectal cancer liver metastasis (CRLM) Tumor microenvironment.
<p><strong>Background and purpose:</strong> While HCC is an inflammation-associated cancer, CRLM develop on permissive healthy liver microenvironment. To evaluate the immune aspects of these two different environments, peripheral blood-(PB), peritumoral-(PT) and tumoral tissues-(TT) from HCC and CRLM patients were evaluated.</p> <p><strong>Methods:</strong> 40 HCC and 34 CRLM were enrolled and freshly TT, PT and PB were collected at the surgery. PB-, PT- and TT-derived CD4<sup>+</sup>CD25<sup>+ </sup>Tregs, M/PMN-MDSC and PB-derived CD4<sup>+</sup>CD25<sup>− </sup>Teffector cells (Teffs) were isolated and characterized. Tregs function was also evaluated in the presence of the CXCR4 inhibitor, Peptide-R29, AMD3100 or anti-PD1. RNA was extracted from PB/PT/TT-tissues and tested for FOXP3, CXCL12, CXCR4, CCL5, IL-15, CXCL5, Arg-1, N-cad, Vim, CXCL8, TGFβ and VEGF-A expression.</p> <p><strong>Results:</strong> In HCC/CRLM-PB higher number of functional Tregs, CD4<sup>+</sup>CD25<sup>hi</sup>FOXP3<sup>+</sup> were detected, although PB-HCC Tregs exert a more suppressive function as compared to CRLM-Tregs. In HCC/CRLM-TT Tregs were highly represented with Activated/ENTPD-1<sup>+</sup>Tregs prevalent in HCC. As compared to CRLM, HCC overexpressed CXCR4 and N-cadherin/Vimentin in a contest rich of arginase and CCL5. Monocytic-MDSCs were highly represented in HCC/CRLM while high Polymorphonuclear-MDSCs were detected only in HCC. Interestingly, CXCR4-PB-Tregs function was impaired in HCC/CRLM by the CXCR4 inhibitor R29.</p> <p><strong>Conclusion:</strong> In HCC and CRLM, peripheral blood, peritumoral and tumoral tissues-Tregs are highly represented and functional. Nevertheless, HCC display a more immunosuppressive TME due to Tregs, MDSCs, intrinsic tumor features (CXCR4, CCL5, arginase) and the contest in which it develops. As CXCR4 is overexpressed in HCC/CRLM tumor/TME cells, CXCR4 inhibitors may be considered for double hits therapy in liver cancer patients.</p>
Development and validation of metabolic models for predicting survival and immune status of hepatocellular carcinoma patients
<p>Supplementary materials for the article titled “Development and validation of metabolic models for predicting survival and immune status of hepatocellular carcinoma patients”</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.